Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YK-029A vs Platinum-based Chemotherapy in EGFR Exon 20 NSCLC
NCT05767892Phase 3Not yet recruiting
- Sponsor
- Suzhou Puhe Biopharma
- Start
- May 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pruvonertinib in non-small cell lung cancer (NSCLC), sponsored by Suzhou Puhe Biopharma. Planned start May 2023; status: not yet recruiting.
02
Drugs
pruvonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05767892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767892.